Penalty Amount
$1,050,000
New York and a coalition of 47 other attorneys general secured settlements with Ascend Laboratories and Mayne Pharma over an alleged scheme to inflate generic drug prices and reduce competition. Mayne agreed to pay $650,000 and Ascend $400,000, with settlement funds distributed to impacted consumers and the companies agreeing to internal antitrust reforms.
Mayne will pay $650,000 and Ascend will pay $400,000, with funds distributed to impacted consumers across coalition states. Each company also agreed to internal reforms, including annual antitrust compliance training.
This action concerns antitrust conduct rather than a privacy violation, so privacy-specific clauses are not implicated by the release. In vendor, distributor, and customer agreements—especially those involving generic pharmaceuticals, pricing, supply, or bids—review clauses requiring independent pricing and bidding decisions, prohibiting coordination or exchange of competitively sensitive information, and requiring compliance with antitrust laws. Consider adding or strengthening antitrust training, certification, audit, and escalation obligations; employee agreements and policies governing competitor contact may also warrant review.
Entity
Ascend Laboratories and Mayne Pharma
Industry
HealthcareOfficial Press Release
https://ag.ny.gov/press-release/2026/attorney-general-james-secures-over-1-million-ascend-laboratories-and-mayne
connecticut et al v aurobindo pharma usa inc et al memorandu
https://ag.ny.gov/sites/default/files/settlements-agreements/connecticut-et-al-v-aurobindo-pharma-usa-inc-et-al-memorandum-2026.pdf
New York Attorney General Enforcement Page
https://ag.ny.gov/press-releases
"October 8, 2026"
"from Ascend Laboratories (Ascend) and Mayne Pharma (Mayne)"
"Mayne will pay $650,000 and Ascend will pay $400,000."
"compliance with antitrust laws"
"to artificially inflate generic drug prices and reduce competition"
$2.6M
New York and Connecticut reached a settlement with Boston Children’s Health Physicians and its IT security provider, XTIUM, after a 2024 breach exposed private information of approximately 825,000 New York residents and 62,871 Connecticut residents. The companies will pay $2.64 million and implement enhanced cybersecurity measures; additional penalties are conditional on violating the settlement.
New York Attorney General Letitia James joined 16 other attorneys general in urging Congress to pass proposed legislation addressing the federal government’s release of Jeffrey Epstein-related records. The press release says DOJ has not fully disclosed the records required by the original law and that personal information of at least 43 victims was exposed in released files; this is a legislative advocacy announcement, not an enforcement action imposing a penalty or remedy.
$1.9M
New York Attorney General Letitia James secured a settlement after an investigation found Dollar General stores routinely charged customers more than advertised or posted prices and issued confusing receipts. Dollar General must donate $1.875 million in food and personal items to Foodlink and implement pricing, receipt, training, and audit reforms.
New York Attorney General Letitia James released an updated guide warning voters that AI-generated election content and chatbots may provide misleading information. This is public guidance, not an enforcement action, and the release describes no penalty or privacy violation.
New York Attorney General Letitia James and a bipartisan coalition of 39 other attorneys general filed a motion in Character Technologies, Inc.’s bankruptcy, citing risks to children and sensitive user information and potential violations of state privacy laws. The coalition asks the court, the company, and any prospective buyer to require meaningful privacy and safety protections; no fine or final remedy is reported.
New York Attorney General Letitia James, the FTC, and six other state attorneys general asked a federal court to hold Martin Shkreli in contempt for allegedly trading pharmaceutical stocks and discussing pharmaceutical companies in violation of his lifetime industry ban. The requested sanctions include divestiture, an accounting of his trading, forfeiture of trading profits, and possible further fines or incarceration; the release describes a request to the court, not a new ruling imposing those measures.